Natural killer (NK) cells play a major role in cancer immunotherapies that involve tumor-
antigen targeting by monoclonal antibodies (mAbs). NK cells express a variety of activating …

Natural killer (NK) cells are potent cytotoxic effector cells for cancer therapy and potentially
for severe viral infections. However, there are technical challenges to obtain sufficient …

Background Preclinical and preliminary clinical data indicate that ch14. 18, a monoclonal
antibody against the tumor-associated disialoganglioside GD2, has activity against …

Immunoglobulin (Ig) G1 antibodies stimulate antibody-dependent cell-mediated cytotoxicity
(ADCC). Cetuximab, an IgG1 isotype monoclonal antibody, is a standard-of-care treatment …

Extensive crosstalk among ErbB/HER receptors suggests that blocking signaling from more
than one family member may be essential to effectively treat cancer and limit drug …

Therapeutic drug monitoring (TDM) provides valuable guidance for dose adjustment of
antibiotics, immunosuppressives, antiepileptics, and other drugs, but its use for traditional …

Natural killer (NK) cells are innate effector lymphocytes that control the growth of major
histocompatibility complex class I negative tumors. We show here that γδ T lymphocytes …

Cetuximab has an established role in the treatment of patients with recurrent/metastatic
colorectal cancer and head and neck squamous cell cancer (HNSCC). However, the long …

Summary CD 25 (also termed IL 2 RA) forms one component of the high‐affinity
heterotrimeric interleukin 2 (IL 2) receptor on activated T cells. Its affinity for IL 2 and cellular …

Overexpression of the epidermal growth factor receptor (EGFR) is a common characteristic
of head and neck squamous cell carcinomas (HNSCC). Cetuximab is a chimeric anti-EGFR …